Amgen Inc. company logo

# 1st Gen Model Amgen Inc. Biological products, except diagnostic

Subscribe >> Deal exit on
Oct. 23, 2017
Deal entry on
Oct. 23, 2017
1.17%Expected margin
69.86% successful of 73 deals
$182.96 Last close price
at 20-oct-2017

AMGN

Model's trade recommendations 0.76% Return for period

14.38% Annual return

$133.50B Market Cap

β 1.36  

AMGN

Model (following trade recommendations)

AMGN

Underlying stock

S&P 500

Index
Return for period 0.76%
-1.79%
1.78%
52wk return 9.46%
15.42%
16.82%
52wk Range
135.22—191.00
2000.54—2399.63
Sortino ratio 2.00
Sharpe ratio 1.17
Norm. RMSE 0.22%
Downside risk 6.90%
Volatility 11.82%
  • 4.60 (2.51%) Div (Yield)
  • BUY Analysts consensus recommendation

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Industry sector: Medical

Sector classification: Biological products, except diagnostic

Deep Learning based analysis and prediction model for Amgen Inc. (AMGN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for AMGN model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 728M
P/E 14.84
Shares Outstanding 730M
% Held by Insiders 0.19%
% Held by Institutions 78.09%
EPS (last reported FY) $11.65
EPS (last reported Q) $3.27
EPS, estimated (last reported Q) $3.09
Total revenues $23 B
Net income $8 B